{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:41:01Z","timestamp":1792194061284,"version":"4.4.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01855-x","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:47:32Z","timestamp":1792190852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR-T-centered sequential therapy: current status, challenges, and future clinical perspectives"],"prefix":"10.1186","volume":"19","author":[{"given":"Lucheng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqiang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianlei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"1","key":"1855_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64\u201373. https:\/\/doi.org\/10.1056\/NEJMra1706169.","journal-title":"N Engl J Med"},{"issue":"9967","key":"1855_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(14)61403-3.","journal-title":"Lancet"},{"issue":"6","key":"1855_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"1855_CR4","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","volume":"10","author":"X Xu","year":"2019","unstructured":"Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, et al. Mechanisms of relapse after CD19 CAR T-Cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front. Immunol. 2019;10:2664. https:\/\/doi.org\/10.3389\/fimmu.2019.02664.","journal-title":"Front. Immunol"},{"issue":"12","key":"1855_CR5","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","volume":"22","author":"M Ruella","year":"2023","unstructured":"Ruella M, Korell F, Porazzi P, Maus MV. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat Rev Drug Discov. 2023;22(12):976\u201395. https:\/\/doi.org\/10.1038\/s41573-023-00807-1.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"1855_CR6","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219\u201326. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0442.","journal-title":"Cancer Discov"},{"issue":"4","key":"1855_CR7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3390\/cells15040380","volume":"15","author":"H Yasui","year":"2026","unstructured":"Yasui H, Doki N, Yan W, Imai K, Ishida T. Determinants of efficacy and optimization of chimeric antigen receptor T-Cell therapy for treating multiple myeloma: current status and future perspectives. Cells. 2026;15(4):380. https:\/\/doi.org\/10.3390\/cells15040380.","journal-title":"Cells"},{"issue":"16","key":"1855_CR8","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1182\/bloodadvances.2023010856","volume":"8","author":"MSY Tan","year":"2024","unstructured":"Tan MSY, Chen Y, Smith EL. Beyond BCMA: newer immune targets in myeloma. Blood Adv. 2024;8(16):4433\u201346. https:\/\/doi.org\/10.1182\/bloodadvances.2023010856.","journal-title":"Blood Adv"},{"issue":"1","key":"1855_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20\u201328. https:\/\/doi.org\/10.1038\/nm.4441.","journal-title":"Nat Med"},{"issue":"13","key":"1855_CR10","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-Targeted CAR T cells for myeloma. N Engl J Med. 2022;387(13):1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2209900.","journal-title":"N Engl J Med"},{"issue":"3","key":"1855_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145\u201361. https:\/\/doi.org\/10.1038\/s41568-020-00323-z.","journal-title":"Nat Rev Cancer"},{"issue":"27","key":"1855_CR12","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1200\/JCO.20.03458","volume":"39","author":"RM Myers","year":"2021","unstructured":"Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, et al. Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-Naive and CAR-Exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol. 2021;39(27):3044\u201355. https:\/\/doi.org\/10.1200\/JCO.20.03458.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1855_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12943-025-02334-6","volume":"24","author":"Y Lu","year":"2025","unstructured":"Lu Y, Zhao F. Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy. Mol Cancer. 2025;24(1):126. https:\/\/doi.org\/10.1186\/s12943-025-02334-6.","journal-title":"Mol Cancer"},{"issue":"6","key":"1855_CR14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372\u201385. https:\/\/doi.org\/10.1038\/s41571-019-0184-6.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1855_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36. https:\/\/doi.org\/10.1186\/2162-3619-1-36.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"1855_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood.2020006770","volume":"137","author":"J Gauthier","year":"2021","unstructured":"Gauthier J, Bezerra ED, Hirayama AV, Fiorenza S, Sheih A, Chou CK, et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood. 2021;137(3):323\u201335. https:\/\/doi.org\/10.1182\/blood.2020006770.","journal-title":"Blood"},{"issue":"18","key":"1855_CR17","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","volume":"392","author":"J Svoboda","year":"2025","unstructured":"Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, et al. Enhanced CAR T-Cell therapy for lymphoma after previous failure. N Engl J Med. 2025;392(18):1824\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2408771.","journal-title":"N Engl J Med"},{"issue":"4","key":"1855_CR18","doi-asserted-by":"publisher","first-page":"201044","DOI":"10.1016\/j.omton.2025.201044","volume":"33","author":"CH Chan","year":"2025","unstructured":"Chan CH, Yang X, Lyu M, Chen Z, Liu Y, Zhang G, et al. Targeting BCMA in multiple myeloma: a comprehensive review of immunotherapeutic strategies and clinical outcomes. Mol Ther Oncol. 2025;33(4):201044. https:\/\/doi.org\/10.1016\/j.omton.2025.201044.","journal-title":"Mol Ther Oncol"},{"issue":"15","key":"1855_CR19","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/bloodadvances.2021004176","volume":"5","author":"N Gazeau","year":"2021","unstructured":"Gazeau N, Beauvais D, Yakoub-Agha I, Mitra S, Campbell TB, Facon T, et al. Effective anti-BCMA retreatment in multiple myeloma. Blood Adv. 2021;5(15):3016\u201320. https:\/\/doi.org\/10.1182\/bloodadvances.2021004176.","journal-title":"Blood Adv"},{"issue":"18","key":"1855_CR20","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.1182\/bloodadvances.2025016712","volume":"9","author":"T Richardson","year":"2025","unstructured":"Richardson T, Holtick U, Frenking JH, Tharmaseelan H, Balke-Want H, Flumann R, et al. Sequential BCMA CAR T-cell therapy in refractory multiple myeloma. Blood Adv. 2025;9(18):4624\u201330. https:\/\/doi.org\/10.1182\/bloodadvances.2025016712.","journal-title":"Blood Adv"},{"issue":"1","key":"1855_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13(1):117. https:\/\/doi.org\/10.1038\/s41408-023-00886-8.","journal-title":"Blood Cancer J"},{"issue":"9","key":"1855_CR22","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1182\/bloodadvances.2023012066","volume":"8","author":"KR Reyes","year":"2024","unstructured":"Reyes KR, Liu YC, Huang CY, Banerjee R, Martin T, Wong SW, et al. Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma. Blood Adv. 2024;8(9):2207\u201316. https:\/\/doi.org\/10.1182\/bloodadvances.2023012066.","journal-title":"Blood Adv"},{"key":"1855_CR23","doi-asserted-by":"publisher","first-page":"1577360","DOI":"10.3389\/fimmu.2025.1577360","volume":"16","author":"X Yuan","year":"2025","unstructured":"Yuan X, Wang F, Zhao P, Yang B, Yang X, Tian T, et al. Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies. Front Immunol. 2025;16:1577360. https:\/\/doi.org\/10.3389\/fimmu.2025.1577360.","journal-title":"Front Immunol"},{"issue":"1","key":"1855_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40164-024-00593-5","volume":"14","author":"T Yang","year":"2025","unstructured":"Yang T, Dong Y, Zhang M, Feng J, Fu S, Xiao P, et al. Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed\/refractory adult B-cell acute lymphoblastic leukemia. Exp Hematol Oncol. 2025;14(1):2. https:\/\/doi.org\/10.1186\/s40164-024-00593-5.","journal-title":"Exp Hematol Oncol"},{"key":"1855_CR25","doi-asserted-by":"publisher","first-page":"117252","DOI":"10.1016\/j.biopha.2024.117252","volume":"178","author":"H Lin","year":"2024","unstructured":"Lin H, Yang X, Ye S, Huang L, Mu W. Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies. Biomed Pharmacother. 2024;178:117252. https:\/\/doi.org\/10.1016\/j.biopha.2024.117252.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"1855_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood.2019003293","volume":"135","author":"J Pan","year":"2020","unstructured":"Pan J, Zuo S, Deng B, Xu X, Li C, Zheng Q, et al. Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL. Blood. 2020;135(5):387\u201391. https:\/\/doi.org\/10.1182\/blood.2019003293.","journal-title":"Blood"},{"issue":"11","key":"1855_CR27","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/S1470-2045(23)00436-9","volume":"24","author":"J Pan","year":"2023","unstructured":"Pan J, Tang K, Luo Y, Seery S, Tan Y, Deng B, et al. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. The Lancet Oncol. 2023;24(11):1229\u201341. https:\/\/doi.org\/10.1016\/S1470-2045(23)00436-9.","journal-title":"The Lancet Oncol"},{"key":"1855_CR28","doi-asserted-by":"publisher","first-page":"1178403","DOI":"10.3389\/fimmu.2023.1178403","volume":"14","author":"NJ Fergusson","year":"2023","unstructured":"Fergusson NJ, Adeel K, Kekre N, Atkins H, Hay KA. A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells. Front Immunol. 2023;14:1178403. https:\/\/doi.org\/10.3389\/fimmu.2023.1178403.","journal-title":"Front Immunol"},{"issue":"6","key":"1855_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/ajh.26160","volume":"96","author":"S Liu","year":"2021","unstructured":"Liu S, Deng B, Yin Z, Lin Y, An L, Liu D, et al. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol. 2021;96(6):671\u201379. https:\/\/doi.org\/10.1002\/ajh.26160.","journal-title":"Am J Hematol"},{"key":"1855_CR30","doi-asserted-by":"publisher","first-page":"1039929","DOI":"10.3389\/fimmu.2022.1039929","volume":"13","author":"L Deng","year":"2022","unstructured":"Deng L, Xiaolin Y, Wu Q, Song X, Li W, Hou Y, et al. Multiple CAR-T cell therapy for acute B-cell lymphoblastic leukemia after hematopoietic stem cell transplantation: a case report. Front. Immunol. 2022;13:1039929. https:\/\/doi.org\/10.3389\/fimmu.2022.1039929.","journal-title":"Front. Immunol"},{"issue":"10450","key":"1855_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","volume":"404","author":"MJ Frank","year":"2024","unstructured":"Frank MJ, Baird JH, Kramer AM, Srinagesh HK, Patel S, Brown AK, et al. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Lancet. 2024;404(10450):353\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(24)00746-3.","journal-title":"Lancet"},{"issue":"6","key":"1855_CR32","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494\u2013506. https:\/\/doi.org\/10.3324\/haematol.2019.243543.","journal-title":"Haematologica"},{"key":"1855_CR33","doi-asserted-by":"publisher","unstructured":"Omidvar L, Mer AH, Mirzaei Y, Sanaye-Pasand MR, Jahandideh S, Hassani M, et al. CD20-directed antibody-drug conjugates in non-hodgkin lymphoma: translating preclinical promise into clinical reality. J Hematol Oncol. 2026;19(1). https:\/\/doi.org\/10.1186\/s13045-026-01807-5.","DOI":"10.1186\/s13045-026-01807-5"},{"issue":"8","key":"1855_CR34","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.jcyt.2025.04.063","volume":"27","author":"F Xue","year":"2025","unstructured":"Xue F, Liu R, Fu Z, Zheng P, Yang F, Feng S, et al. Sequential CD19-20 CAR T-cell therapy for refractory\/relapsed diffuse large B-cell lymphoma. Cytotherapy. 2025;27(8):910\u201316. https:\/\/doi.org\/10.1016\/j.jcyt.2025.04.063.","journal-title":"Cytotherapy"},{"issue":"3","key":"1855_CR35","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1182\/bloodadvances.2021004557","volume":"6","author":"Y Liu","year":"2022","unstructured":"Liu Y, Deng B, Hu B, Zhang W, Zhu Q, Liu Y, et al. Sequential different B-cell antigen\u2013targeted CAR T-cell therapy for pediatric refractory\/relapsed burkitt lymphoma. Blood Adv. 2022;6(3):717\u201330. https:\/\/doi.org\/10.1182\/bloodadvances.2021004557.","journal-title":"Blood Adv"},{"key":"1855_CR36","doi-asserted-by":"publisher","first-page":"640166","DOI":"10.3389\/fonc.2021.640166","volume":"11","author":"Y Meng","year":"2021","unstructured":"Meng Y, Deng B, Rong L, Li C, Song W, Ling Z, et al. Short-interval sequential CAR-T cell infusion May enhance prior CAR-T cell expansion to augment anti-lymphoma response in B-NHL. Front Oncol. 2021;11:640166. https:\/\/doi.org\/10.3389\/fonc.2021.640166.","journal-title":"Front Oncol"},{"issue":"8","key":"1855_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6004\/jnccn.2026.7004","volume":"24","author":"KC Miller","year":"2026","unstructured":"Miller KC, Firestone RS, Hultcrantz M. Incorporating the next generation of immunotherapies into the treatment of multiple myeloma. J Natl Compr Canc Netw. 2026;24(8):1\u20138. https:\/\/doi.org\/10.6004\/jnccn.2026.7004.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"1855_CR38","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/s41375-026-02920-7","volume":"40","author":"U Munawar","year":"2026","unstructured":"Munawar U, Thurner J, Nerreter S, Nerreter T, Leipold AM, Han S, et al. Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy. Leukemia. 2026;40(6):1227\u201339. https:\/\/doi.org\/10.1038\/s41375-026-02920-7.","journal-title":"Leukemia"},{"issue":"9","key":"1855_CR39","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29(9):2295\u2013306. https:\/\/doi.org\/10.1038\/s41591-023-02491-5.","journal-title":"Nat Med"},{"key":"1855_CR40","doi-asserted-by":"publisher","unstructured":"Zhang M, Wei G, Zhou L, Zhou J, Chen S, Zhang W, et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023;10(2):e107\u201316. https:\/\/doi.org\/10.1016\/S2352-3026(22)00372-6.","DOI":"10.1016\/S2352-3026(22)00372-6"},{"key":"1855_CR41","doi-asserted-by":"publisher","unstructured":"Xia J, Sun Q, Zhou D, Li H, Wang Y, Qi Y, et al. Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2025;12(5):e365\u201375. https:\/\/doi.org\/10.1016\/S2352-3026(25)00048-1.","DOI":"10.1016\/S2352-3026(25)00048-1"},{"issue":"1","key":"1855_CR42","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41408-024-01197-2","volume":"14","author":"M Merz","year":"2024","unstructured":"Merz M, Dima D, Hashmi H, Ahmed N, Stolzel F, Holderried TAW, et al. Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy. Blood Cancer J. 2024;14(1):214. https:\/\/doi.org\/10.1038\/s41408-024-01197-2.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1855_CR43","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1158\/2643-3230.BCD-25-0461","volume":"7","author":"M Merz","year":"2026","unstructured":"Merz M, Jelinek T, Pabst T, Teipel R, Albici AM, von Tresckow B, et al. Outcomes of CAR T-cell therapy and Bispecific antibodies as single-modality and sequential strategies in relapsed\/refractory multiple myeloma. Blood Cancer Discov. 2026;7(5):697\u2013710. https:\/\/doi.org\/10.1158\/2643-3230.BCD-25-0461.","journal-title":"Blood Cancer Discov"},{"key":"1855_CR44","doi-asserted-by":"publisher","unstructured":"van de DonkN, de Larrea C F. Sequential CAR T-cell therapy in myeloma: going from BCMA to GPRC5D. Lancet Haematol. 2025;12(5):e323\u201324. https:\/\/doi.org\/10.1016\/S2352-3026(25)00074-2.","DOI":"10.1016\/S2352-3026(25)00074-2"},{"issue":"1","key":"1855_CR45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","volume":"12","author":"W Li","year":"2023","unstructured":"Li W, Zhang B, Cao W, Zhang W, Li T, Liu L, et al. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing. Exp Hematol Oncol. 2023;12(1):44. https:\/\/doi.org\/10.1186\/s40164-023-00402-5.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"1855_CR46","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","volume":"39","author":"LJ Costa","year":"2025","unstructured":"Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, et al. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39(3):543\u201354. https:\/\/doi.org\/10.1038\/s41375-024-02482-6.","journal-title":"Leukemia"},{"issue":"1","key":"1855_CR47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","volume":"15","author":"D Kegyes","year":"2022","unstructured":"Kegyes D, Constantinescu C, Vrancken L, Rasche L, Gregoire C, Tigu B, et al. Patient selection for CAR T or BiTE therapy in multiple myeloma: which treatment for each patient? J Hematol Oncol. 2022;15(1):78. https:\/\/doi.org\/10.1186\/s13045-022-01296-2.","journal-title":"J Hematol Oncol"},{"issue":"24","key":"1855_CR48","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1182\/blood.2025029360","volume":"146","author":"A Chari","year":"2025","unstructured":"Chari A, van de Donk N, Dholaria B, Weisel K, Mateos MV, Goldschmidt H, et al. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. Blood. 2025;146(24):2902\u201313. https:\/\/doi.org\/10.1182\/blood.2025029360.","journal-title":"Blood"},{"issue":"16","key":"1855_CR49","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","volume":"7","author":"T Glisovic-Aplenc","year":"2023","unstructured":"Glisovic-Aplenc T, Diorio C, Chukinas JA, Veliz K, Shestova O, Shen F, et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv. 2023;7(16):4418\u201330. https:\/\/doi.org\/10.1182\/bloodadvances.2022007059.","journal-title":"Blood Adv"},{"issue":"7","key":"1855_CR50","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1182\/blood.2024025536","volume":"146","author":"C Kasap","year":"2025","unstructured":"Kasap C, Izgutdina A, Patino-Escobar B, Kang AS, Chilakapati N, Akagi N, et al. Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells. Blood. 2025;146(7):819\u201333. https:\/\/doi.org\/10.1182\/blood.2024025536.","journal-title":"Blood"},{"issue":"2","key":"1855_CR51","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cam4.3624","volume":"10","author":"L Yan","year":"2021","unstructured":"Yan L, Qu S, Shang J, Shi X, Kang L, Xu N, et al. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and\/or refractory myeloma. Cancer Med. 2021;10(2):563\u201374. https:\/\/doi.org\/10.1002\/cam4.3624.","journal-title":"Cancer Med"},{"issue":"5","key":"1855_CR52","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ajh.26486","volume":"97","author":"X Shi","year":"2022","unstructured":"Shi X, Yan L, Shang J, Kang L, Yan Z, Jin S, et al. Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. Am J Hematol. 2022;97(5):537\u201347. https:\/\/doi.org\/10.1002\/ajh.26486.","journal-title":"Am J Hematol"},{"issue":"3","key":"1855_CR53","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130(3):285\u201396. https:\/\/doi.org\/10.1182\/blood-2017-01-761320.","journal-title":"Blood"},{"issue":"16","key":"1855_CR54","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhang M, Yang T, Mo Z, Wei G, Jing R, et al. Sequential CD7 CAR T-Cell therapy and allogeneic HSCT without GVHD prophylaxis. N Engl J Med. 2024;390(16):1467\u201380. https:\/\/doi.org\/10.1056\/NEJMoa2313812.","journal-title":"N Engl J Med"},{"issue":"1","key":"1855_CR55","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41591-024-03282-2","volume":"31","author":"J Pan","year":"2025","unstructured":"Pan J, Tan Y, Shan L, Seery S, Deng B, Ling Z, et al. Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial. Nat Med. 2025;31(1):126\u201336. https:\/\/doi.org\/10.1038\/s41591-024-03282-2.","journal-title":"Nat Med"},{"issue":"1","key":"1855_CR56","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40164-024-00584-6","volume":"13","author":"H Zheng","year":"2024","unstructured":"Zheng H, Zhao H, Han S, Kong D, Zhang Q, Zhang M, et al. Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies. Exp Hematol Oncol. 2024;13(1):117. https:\/\/doi.org\/10.1186\/s40164-024-00584-6.","journal-title":"Exp Hematol Oncol"},{"key":"1855_CR57","doi-asserted-by":"publisher","first-page":"104824","DOI":"10.1016\/j.critrevonc.2025.104824","volume":"214","author":"S Wang","year":"2025","unstructured":"Wang S, Li X, Ning H, Wu Y. Dual-target CAR-T cell therapy: a new strategy to improve the therapeutic effect of hematological malignancies. Crit Rev Oncol Hematol. 2025;214:104824. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104824.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1855_CR58","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s40164-025-00725-5","volume":"14","author":"Y Chen","year":"2025","unstructured":"Chen Y, Xin Q, Qiu J, Zhu M, Li Z, Qiu J, et al. In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies. Exp Hematol Oncol. 2025;14(1):133. https:\/\/doi.org\/10.1186\/s40164-025-00725-5.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"1855_CR59","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-024-01542-9","volume":"17","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Paruzzo L, Patel V, Svoboda J, Chong ER, Fardella E, et al. Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel. J Hematol Oncol. 2024;17(1):19. https:\/\/doi.org\/10.1186\/s13045-024-01542-9.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"1855_CR60","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1038\/s41375-025-02720-5","volume":"39","author":"R Kadirkamanathan","year":"2025","unstructured":"Kadirkamanathan R, Georgiadis C, Kloos A, Joshi A, Etuk A, Preece R, et al. Base edited \u201cuniversal\u201d donor CAR T-cell strategies for acute myeloid leukaemia. Leukemia. 2025;39(12):2978\u201387. https:\/\/doi.org\/10.1038\/s41375-025-02720-5.","journal-title":"Leukemia"},{"issue":"1","key":"1855_CR61","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40164-024-00536-0","volume":"13","author":"D Zhou","year":"2024","unstructured":"Zhou D, Zhu X, Xiao Y. CAR-T cell combination therapies in hematologic malignancies. Exp Hematol Oncol. 2024;13(1):69. https:\/\/doi.org\/10.1186\/s40164-024-00536-0.","journal-title":"Exp Hematol Oncol"},{"issue":"24","key":"1855_CR62","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","volume":"127","author":"X Wang","year":"2016","unstructured":"Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016;127(24):2980\u201390.","journal-title":"Blood"},{"issue":"7","key":"1855_CR63","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood.2018883421","volume":"134","author":"CS Sauter","year":"2019","unstructured":"Sauter CS, Senechal B, Riviere I, Ni A, Bernal Y, Wang X, et al. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2019;134(7):626\u201335. https:\/\/doi.org\/10.1182\/blood.2018883421.","journal-title":"Blood"},{"key":"1855_CR64","doi-asserted-by":"publisher","unstructured":"Cao Y, Xiao Y, Wang N, Wang G, Huang L, Hong Z, et al. CD19\/CD22 chimeric antigen receptor T cell cocktail therapy following autologous transplantation in patients with relapsed\/refractory aggressive B cell lymphomas. Transpl Cell Ther. 2021;27(11):.e910.1\u2013910.11. https:\/\/doi.org\/10.1016\/j.jtct.2021.08.012.","DOI":"10.1016\/j.jtct.2021.08.012"},{"issue":"7","key":"1855_CR65","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41408-021-00523-2","volume":"11","author":"J Wu","year":"2021","unstructured":"Wu J, Meng F, Cao Y, Zhang Y, Zhu X, Wang N, et al. Sequential CD19\/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. Blood Cancer J. 2021;11(7):131. https:\/\/doi.org\/10.1038\/s41408-021-00523-2.","journal-title":"Blood Cancer J"},{"key":"1855_CR66","doi-asserted-by":"publisher","first-page":"1127868","DOI":"10.3389\/fimmu.2023.1127868","volume":"14","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Zhu X, Liu B, Zhang Y, Xiao Y. Case report: sandwich therapy of CAR-T combined with ASCT: sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed\/refractory Burkitt\u2019s lymphoma with TP53 mutations. Front Immunol. 2023;14:1127868. https:\/\/doi.org\/10.3389\/fimmu.2023.1127868.","journal-title":"Front Immunol"},{"issue":"10","key":"1855_CR67","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/ajh.25582","volume":"94","author":"H Jiang","year":"2019","unstructured":"Jiang H, Li C, Yin P, Guo T, Liu L, Xia L, et al. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial. Am J Hematol. 2019;94(10):1113\u201322. https:\/\/doi.org\/10.1002\/ajh.25582.","journal-title":"Am J Hematol"},{"key":"1855_CR68","doi-asserted-by":"publisher","first-page":"755549","DOI":"10.3389\/fimmu.2021.755549","volume":"12","author":"W Chen","year":"2021","unstructured":"Chen W, Ma Y, Shen Z, Chen H, Ma R, Yan D, et al. Humanized anti-CD19 CAR-T cell therapy and sequential allogeneic hematopoietic stem cell transplantation achieved long-term survival in refractory and relapsed B lymphocytic leukemia: a retrospective study of CAR-T cell therapy. Front Immunol. 2021;12:755549. https:\/\/doi.org\/10.3389\/fimmu.2021.755549.","journal-title":"Front Immunol"},{"key":"1855_CR69","doi-asserted-by":"publisher","first-page":"605766","DOI":"10.3389\/fimmu.2021.605766","volume":"12","author":"YL Zhao","year":"2021","unstructured":"Zhao YL, Liu DY, Sun RJ, Zhang JP, Zhou JR, Wei ZJ, et al. Integrating CAR T-Cell therapy and transplantation: comparisons of safety and long-Term efficacy of allogeneic hematopoietic stem cell transplantation after CAR T-Cell or chemotherapy-based complete remission in B-Cell acute lymphoblastic leukemia. Front Immunol. 2021;12:605766. https:\/\/doi.org\/10.3389\/fimmu.2021.605766.","journal-title":"Front Immunol"},{"issue":"1","key":"1855_CR70","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/CJI.0000000000000284","volume":"43","author":"C Qu","year":"2020","unstructured":"Qu C, Ping N, Kang L, Liu H, Qin S, Wu Q, et al. Radiation priming chimeric antigen receptor T-Cell therapy in relapsed\/refractory diffuse large B-Cell lymphoma with high tumor burden. J Immunother. 2020;43(1):32\u201337. https:\/\/doi.org\/10.1097\/CJI.0000000000000284.","journal-title":"J Immunother"},{"issue":"4","key":"1855_CR71","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-17-1788","volume":"78","author":"T Weiss","year":"2018","unstructured":"Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P. NKG2D-Based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res. 2018;78(4):1031\u201343. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1788.","journal-title":"Cancer Res"},{"issue":"18","key":"1855_CR72","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-16-1673","volume":"23","author":"SJ Dovedi","year":"2017","unstructured":"Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, et al. Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade. Clin Cancer Res. 2017;23(18):5514\u201326. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1673.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1855_CR73","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.4049\/jimmunol.180.5.3132","volume":"180","author":"AA Lugade","year":"2008","unstructured":"Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-\u03b3 production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008;180(5):3132\u201339. https:\/\/doi.org\/10.4049\/jimmunol.180.5.3132.","journal-title":"J Immunol"},{"issue":"4","key":"1855_CR74","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas RA. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017.","journal-title":"Cell"},{"issue":"20","key":"1855_CR75","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","volume":"19","author":"LB John","year":"2013","unstructured":"John LB, Devaud C, Duong CPM, Yong CS, Beavis PA, Haynes NM, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19(20):5636\u201346. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0458.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1855_CR76","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-021-01120-3","volume":"14","author":"C Wang","year":"2021","unstructured":"Wang C, Shi F, Liu Y, Zhang Y, Dong L, Li X, et al. Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed\/relapsed after CART19\/20 therapy. J Hematol Oncol. 2021;14(1):106. https:\/\/doi.org\/10.1186\/s13045-021-01120-3.","journal-title":"J Hematol Oncol"},{"issue":"16","key":"1855_CR77","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1182\/bloodadvances.2023010016","volume":"7","author":"A Major","year":"2023","unstructured":"Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, et al. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023;7(16):4528\u201338. https:\/\/doi.org\/10.1182\/bloodadvances.2023010016.","journal-title":"Blood Adv"},{"key":"1855_CR78","doi-asserted-by":"publisher","unstructured":"Iacoboni G, Iraola-Truchuelo J, O\u2019reilly M, Navarro V, Menne T, Kwon M, et al. Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy. Hemasphere. 2024;8(5):e62. https:\/\/doi.org\/10.1002\/hem3.62.","DOI":"10.1002\/hem3.62"},{"issue":"16","key":"1855_CR79","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood.2024024952","volume":"144","author":"H Srinagesh","year":"2024","unstructured":"Srinagesh H, Jackson C, Shiraz P, Jeyakumar N, Hamilton M, Egeler E, et al. A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia. Blood. 2024;144(16):1689\u201398. https:\/\/doi.org\/10.1182\/blood.2024024952.","journal-title":"Blood"},{"issue":"9","key":"1855_CR80","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19(9):589\u2013608. https:\/\/doi.org\/10.1038\/s41573-020-0073-9.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"1855_CR81","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s00262-023-03461-z","volume":"72","author":"D Awuah","year":"2023","unstructured":"Awuah D, Minnix M, Caserta E, Tandoh T, Adhikarla V, Poku E, et al. Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma. Immunother Cancer Immunol Immunother. 2023;72(8):2841\u201349. https:\/\/doi.org\/10.1007\/s00262-023-03461-z.","journal-title":"Immunother Cancer Immunol Immunother"},{"issue":"1","key":"1855_CR82","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41408-023-00819-5","volume":"13","author":"S Liu","year":"2023","unstructured":"Liu S, Zhang X, Dai H, Cui W, Yin J, Li Z, et al. Which one is better for refractory\/relapsed acute B-cell lymphoblastic leukemia: single-target (CD19) or dual-target (tandem or sequential CD19\/CD22) CAR T-cell therapy? Blood Cancer J. 2023;13(1):60. https:\/\/doi.org\/10.1038\/s41408-023-00819-5.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1855_CR83","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41375-021-01345-8","volume":"36","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wang Y, Liu Y, Tong C, Wang C, Guo Y, et al. Long-term activity of tandem CD19\/CD20 CAR therapy in refractory\/relapsed B-cell lymphoma: a single-arm, phase 1\u20132 trial. Leukemia. 2022;36(1):189\u201396. https:\/\/doi.org\/10.1038\/s41375-021-01345-8.","journal-title":"Leukemia"},{"issue":"2","key":"1855_CR84","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/blood.2023020621","volume":"143","author":"S Ghorashian","year":"2024","unstructured":"Ghorashian S, Lucchini G, Richardson R, Nguyen K, Terris C, Guvenel A, et al. CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL. Blood. 2024;143(2):118\u201323. https:\/\/doi.org\/10.1182\/blood.2023020621.","journal-title":"Blood"},{"issue":"1","key":"1855_CR85","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1182\/blood.2024024517","volume":"145","author":"AJ Lamble","year":"2025","unstructured":"Lamble AJ, Kovach AE, Shah NN. How I treat postimmunotherapy relapsed B-ALL. Blood. 2025;145(1):64\u201374. https:\/\/doi.org\/10.1182\/blood.2024024517.","journal-title":"Blood"},{"issue":"22","key":"1855_CR86","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","volume":"3","author":"V Pillai","year":"2019","unstructured":"Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019;3(22):3539\u201349. https:\/\/doi.org\/10.1182\/bloodadvances.2019000692.","journal-title":"Blood Adv"},{"key":"1855_CR87","doi-asserted-by":"publisher","unstructured":"Rana MS, Fernandez-Pol S, Jensen A, Hovanky V, Velayati A, Oak JS, et al. Dynamics of BCMA expression in patients with relapsed\/refractory multiple myeloma receiving BCMA-directed CAR-T therapy. Blood Cancer J. 2026;16(1). https:\/\/doi.org\/10.1038\/s41408-026-01474-2.","DOI":"10.1038\/s41408-026-01474-2"},{"issue":"17","key":"1855_CR88","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-18-3784","volume":"25","author":"S Ramakrishna","year":"2019","unstructured":"Ramakrishna S, Highfill SL, Walsh Z, Nguyen SM, Lei H, Shern JF, et al. Modulation of target antigen density improves CAR T-cell functionality and persistence. Clin Cancer Res. 2019;25(17):5329\u201341. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3784.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1855_CR89","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41408-021-00465-9","volume":"11","author":"Y Tan","year":"2021","unstructured":"Tan Y, Cai H, Li C, Deng B, Song W, Ling Z, et al. A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL. Blood Cancer J. 2021;11(4):71. https:\/\/doi.org\/10.1038\/s41408-021-00465-9.","journal-title":"Blood Cancer J"},{"issue":"4","key":"1855_CR90","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1182\/blood.2024026655","volume":"146","author":"SK Silbert","year":"2025","unstructured":"Silbert SK, Rankin AW, Hoang CN, Semchenkova A, Myers RM, Zerkalenkova E, et al. Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia. Blood. 2025;146(4):437\u201355. https:\/\/doi.org\/10.1182\/blood.2024026655.","journal-title":"Blood"},{"issue":"7","key":"1855_CR91","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2021.06.012","volume":"39","author":"GM Delgoffe","year":"2021","unstructured":"Delgoffe GM, Xu C, Mackall CL, Green MR, Gottschalk S, Speiser DE, et al. The role of exhaustion in CAR T cell therapy. Cancer Cell. 2021;39(7):885\u201388. https:\/\/doi.org\/10.1016\/j.ccell.2021.06.012.","journal-title":"Cancer Cell"},{"issue":"8","key":"1855_CR92","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399. https:\/\/doi.org\/10.1038\/nri3862.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"1855_CR93","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining \u2018T cell exhaustion\u2019. Nat Rev Immunol. 2019;19(11):665\u201374. https:\/\/doi.org\/10.1038\/s41577-019-0221-9.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"1855_CR94","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/s41590-026-02548-w","volume":"27","author":"CS Frazee","year":"2026","unstructured":"Frazee CS, Chen S, Berry CT, Lee CS, Banciella RA, Ngo L, et al. Fate induction through asymmetric T cell division is modulated by chimeric antigen receptor costimulatory domains. Nat Immunol. 2026;27(7):1433\u201348. https:\/\/doi.org\/10.1038\/s41590-026-02548-w.","journal-title":"Nat Immunol"},{"issue":"6","key":"1855_CR95","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581\u201390. https:\/\/doi.org\/10.1038\/nm.3838.","journal-title":"Nat Med"},{"issue":"8","key":"1855_CR96","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/2159-8290.CD-21-1586","volume":"12","author":"Z Jackson","year":"2022","unstructured":"Jackson Z, Hong C, Schauner R, Dropulic B, Caimi PF, de Lima M, et al. Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with Non-Hodgkin Lymphoma. Cancer Discov. 2022;12(8):1886\u2013903. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1586.","journal-title":"Cancer Discov"},{"issue":"1","key":"1855_CR97","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12943-022-01655-0","volume":"21","author":"VC Jiang","year":"2022","unstructured":"Jiang VC, Hao D, Jain P, Li Y, Cai Q, Yao Y, et al. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Mol Cancer. 2022;21(1):185. https:\/\/doi.org\/10.1186\/s12943-022-01655-0.","journal-title":"Mol Cancer"},{"issue":"6","key":"1855_CR98","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, et al. The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function. Cancer Cell. 2014;26(6):923\u201337. https:\/\/doi.org\/10.1016\/j.ccell.2014.10.018.","journal-title":"Cancer Cell"},{"issue":"5","key":"1855_CR99","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563\u201371. https:\/\/doi.org\/10.1038\/s41591-018-0010-1.","journal-title":"Nat Med"},{"issue":"6","key":"1855_CR100","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","volume":"18","author":"DL Wagner","year":"2021","unstructured":"Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, et al. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021;18(6):379\u201393. https:\/\/doi.org\/10.1038\/s41571-021-00476-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7786","key":"1855_CR101","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, et al. C-jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576(7786):293\u2013300. https:\/\/doi.org\/10.1038\/s41586-019-1805-z.","journal-title":"Nature"},{"issue":"22","key":"1855_CR102","doi-asserted-by":"publisher","first-page":"5083","DOI":"10.1158\/1078-0432.CCR-24-0830","volume":"30","author":"H Hubbeling","year":"2024","unstructured":"Hubbeling H, Leithner D, Silverman EA, Flynn J, Devlin S, Shah G, et al. Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-Cell outcomes in large B-Cell lymphoma. Clin Cancer Res. 2024;30(22):5083\u201393. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0830.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"1855_CR103","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021;137(19):2621\u201333. https:\/\/doi.org\/10.1182\/blood.2020007445.","journal-title":"Blood"},{"issue":"9","key":"1855_CR104","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med. 2022;28(9):1872\u201382. https:\/\/doi.org\/10.1038\/s41591-022-01916-x.","journal-title":"Nat Med"},{"issue":"8","key":"1855_CR105","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.ccell.2025.05.013","volume":"43","author":"D Stahl","year":"2025","unstructured":"Stahl D, Godel P, Balke-Want H, Gholamipoorfard R, Segbers P, Tetenborg L, et al. CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma. Cancer Cell. 2025;43(8):1476\u201394.e10. https:\/\/doi.org\/10.1016\/j.ccell.2025.05.013.","journal-title":"Cancer Cell"},{"issue":"6","key":"1855_CR106","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","volume":"3","author":"KM Dhodapkar","year":"2022","unstructured":"Dhodapkar KM, Cohen AD, Kaushal A, Garfall AL, Manalo RJ, Carr AR, et al. Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma. Blood Cancer Discov. 2022;3(6):490\u2013501. https:\/\/doi.org\/10.1158\/2643-3230.BCD-22-0018.","journal-title":"Blood Cancer Discov"},{"issue":"8","key":"1855_CR107","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1182\/blood.2023021672","volume":"143","author":"J Duell","year":"2024","unstructured":"Duell J, Leipold AM, Appenzeller S, Fuhr V, Rauert-Wunderlich H, Da via M, et al. Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell\u2013redirecting therapy. Blood. 2024;143(8):685\u201396. https:\/\/doi.org\/10.1182\/blood.2023021672.","journal-title":"Blood"},{"issue":"1","key":"1855_CR108","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12(1):868. https:\/\/doi.org\/10.1038\/s41467-021-21177-5.","journal-title":"Nat Commun"},{"issue":"1","key":"1855_CR109","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12885-022-09489-1","volume":"22","author":"L An","year":"2022","unstructured":"An L, Lin Y, Deng B, Yin Z, Zhao D, Ling Z, et al. Humanized CD19 CAR-T cells in relapsed\/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy. BMC Cancer. 2022;22(1):393. https:\/\/doi.org\/10.1186\/s12885-022-09489-1.","journal-title":"BMC Cancer"},{"issue":"27","key":"1855_CR110","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1200\/JCO.21.00377","volume":"39","author":"MJ Frank","year":"2021","unstructured":"Frank MJ, Hossain NM, Bukhari A, Dean E, Spiegel JY, Claire GK, et al. Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-Cell lymphoma: results of a prospective multi-institutional trial. JCO. 2021;39(27):3034\u201343. https:\/\/doi.org\/10.1200\/JCO.21.00377.","journal-title":"JCO"},{"key":"1855_CR111","doi-asserted-by":"publisher","unstructured":"Zou H, Liu W, Wang X, Wang Y, Wang C, Qiu C, et al. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy. J Immunother Cancer. 2024;12(3):e008450. https:\/\/doi.org\/10.1136\/jitc-2023-008450.","DOI":"10.1136\/jitc-2023-008450"},{"issue":"1","key":"1855_CR112","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1038\/s41467-025-56486-6","volume":"16","author":"H Hosoya","year":"2025","unstructured":"Hosoya H, Carleton M, Tanaka K, Sworder B, Syal S, Sahaf B, et al. Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma. Nat Commun. 2025;16(1):1824. https:\/\/doi.org\/10.1038\/s41467-025-56486-6.","journal-title":"Nat Commun"},{"issue":"7","key":"1855_CR113","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00262-023-03418-2","volume":"72","author":"J Jin","year":"2023","unstructured":"Jin J, Liu T, Cheng J, Meng J, Wang N, Huang L, et al. MIP3\u03b1 as an early prognostic predictor for patients with B-cell malignancies receiving CD19\/CD22-redirected CAR-T cell cocktail therapy. Immunother Cancer Immunol Immunother. 2023;72(7):2245\u201356. https:\/\/doi.org\/10.1007\/s00262-023-03418-2.","journal-title":"Immunother Cancer Immunol Immunother"},{"issue":"22","key":"1855_CR114","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.1182\/bloodadvances.2025016375","volume":"9","author":"M Wang","year":"2025","unstructured":"Wang M, Komanduri KV, Datta D, Patel A, Whitaker B, Belov A, et al. An AI model classifies risks of early relapse post\u2013CAR T-cell therapy in a multicenter real-world population with DLBCL. Blood Adv. 2025;9(22):5837\u201352. https:\/\/doi.org\/10.1182\/bloodadvances.2025016375.","journal-title":"Blood Adv"},{"issue":"14","key":"1855_CR115","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1182\/bloodadvances.2018017004","volume":"2","author":"JP Zhang","year":"2018","unstructured":"Zhang JP, Zhang R, Tsao ST, Liu YC, Chen X, Lu DP, et al. Sequential allogeneic and autologous CAR-T\u2013cell therapy to treat an immune-compromised leukemic patient. Blood Adv. 2018;2(14):1691\u201395. https:\/\/doi.org\/10.1182\/bloodadvances.2018017004.","journal-title":"Blood Adv"},{"issue":"10","key":"1855_CR116","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1182\/blood.2025028387","volume":"146","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi A, Aldoss I, Maude SL, Bhojwani D, Wayne AS, Bajel A, et al. Phase 1\/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed\/refractory T-cell malignancies. Blood. 2025;146(10):1163\u201373. https:\/\/doi.org\/10.1182\/blood.2025028387.","journal-title":"Blood"},{"issue":"6576","key":"1855_CR117","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tombacz I, Yadegari A, Mendez Fernandez PO, Shewale SV, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91\u201396. https:\/\/doi.org\/10.1126\/science.abm0594.","journal-title":"Science"},{"issue":"9","key":"1855_CR118","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood.2024024523","volume":"144","author":"CJ Nicolai","year":"2024","unstructured":"Nicolai CJ, Parker MH, Qin J, Tang W, Ulrich-Lewis JT, Gottschalk RJ, et al. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood. 2024;144(9):977\u201387. https:\/\/doi.org\/10.1182\/blood.2024024523.","journal-title":"Blood"},{"key":"1855_CR119","doi-asserted-by":"publisher","unstructured":"Ortiz-Maldonado V, Liang EC, Huang JJ, Jeon Y, Hirayama AV, Kimble EL, et al. A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma. Haematologica. 2026. https:\/\/doi.org\/10.3324\/haematol.2025.300321.","DOI":"10.3324\/haematol.2025.300321"},{"issue":"14","key":"1855_CR120","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1182\/blood.2025028790","volume":"146","author":"C Roddie","year":"2025","unstructured":"Roddie C, Dias J, O\u2019reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, et al. Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion. Blood. 2025;146(14):1664\u201376. https:\/\/doi.org\/10.1182\/blood.2025028790.","journal-title":"Blood"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01855-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01855-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01855-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:47:39Z","timestamp":1792190859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01855-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":120,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1855"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01855-x","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"22 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"85"}}